Skip to content

Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04445610
Enrollment
60
Registered
2020-06-24
Start date
2020-07-01
Completion date
2020-11-01
Last updated
2020-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus (COVID-19)

Brief summary

The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Detailed description

Objectives: 1. To identify Measles IgG titre in SARS-COV2 infected patients . 2. correlate level of Measles IgG titre with the clinical severity of COVID-19 disease. Secondary Objective To find an association of the postulated protective role of measles vaccine and SARS-COV2 infection Criteria: Inclusion criteria:included patients would be divided into 3 groups according to clinical severity of COVID-19 disease (mild ,moderate & severe) * All patients with confirmed COVID 19 confirmed by positive PCR . . * Any age or gender. Exclusion criteria: \- Any patient refusing to be involved in the study. Methods: * Informed consent will be taken from each subject * Full clinical examination. * Evaluation of Measles Antibody Titer: The measles virus IgG antibody titer will be determined quantitatively by ELISA for quantitative determination of IgG class antibodies against Measles virus in human serum or plasma (citrate, heparin). \- Anonymous data will be retrieved from the admitted patients' files, such as: * CBC, CRP, AST, ALT, ESR, Serum ferritin & SARS CoV 2 RNA PCR swab results. * Chest X ray and/or CT chest.

Interventions

None listed

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* All patients with confirmed COVID 19. * Any age or gender

Exclusion criteria

* \- Any patient refusing to be involved in the study

Design outcomes

Primary

MeasureTime frameDescription
Viral clearance6 monthsAchievement of two consecutive negative PCR results for COVID 19 and discharge from hospital

Countries

Egypt

Contacts

Primary ContactAmira Al Balakosy, MD
drbalakosy@gmail.com01221977455

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026